Ratiopharm B.V. Sustainability Profile
Ratiopharm B.V., a prominent player in the pharmaceutical industry, is headquartered in the Netherlands (NL) and operates extensively across Europe. Founded in 1993, the company has established itself as a trusted provider of generic medications, focusing on high-quality, affordable healthcare solutions. Ratiopharm's core offerings include a diverse range of prescription and over-the-counter products, distinguished by their rigorous quality standards and commitment to patient safety. The company has achieved significant milestones, including numerous certifications that underscore its dedication to excellence in pharmaceutical manufacturing. With a strong market position, Ratiopharm B.V. is recognised for its innovative approach to generic drug development, contributing to improved access to essential medications for patients across various regions.
DitchCarbon Score
How does Ratiopharm B.V.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ratiopharm B.V.'s score of 82 is higher than 90% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ratiopharm B.V., headquartered in the Netherlands, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is part of a corporate family that includes Teva Pharmaceutical Industries Limited, from which it inherits its climate commitments and performance metrics. As a merged entity, Ratiopharm B.V. aligns its climate initiatives with those of Teva Pharmaceutical Industries Limited. However, no specific reduction targets or achievements have been documented for Ratiopharm B.V. itself. The company does not have any publicly stated Science-Based Targets Initiative (SBTi) reduction targets or commitments to climate pledges. In the context of the pharmaceutical industry, Ratiopharm B.V. is expected to adhere to the broader sustainability goals set by its parent company, Teva, which may include initiatives aimed at reducing carbon emissions across Scope 1, 2, and 3 categories. However, without specific data or targets, the details of these commitments remain vague. Overall, Ratiopharm B.V. is positioned within a framework of climate responsibility through its association with Teva Pharmaceutical Industries Limited, but lacks independent emissions reporting or defined reduction strategies at this time.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 438,420,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 613,541,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Ratiopharm B.V.'s Industry?
How Carbon Intensive is Ratiopharm B.V.'s Location?
Ratiopharm B.V.'s Scope 3 Categories Breakdown
Ratiopharm B.V.'s Scope 3 emissions, which decreased by 6% last year and decreased by approximately 24% since 2020, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 61% of Scope 3 emissions.
Top Scope 3 Categories
Ratiopharm B.V.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Ratiopharm B.V. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
